<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="117643">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01868269</url>
  </required_header>
  <id_info>
    <org_study_id>IC 2011-02</org_study_id>
    <nct_id>NCT01868269</nct_id>
  </id_info>
  <brief_title>Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)</brief_title>
  <official_title>Multinational European Trial for Children With the Opsoclonus Myoclonus Syndrome / Dancing Eye Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Curie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Curie</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The OMS/DES study is a multinational European Trial for Children with the Opsoclonus
      Myoclonus Syndrome / Dancing Eye Syndrome.

      This trial brought on the way by specialists of the EPNS (European Paediatric Neurology
      Society), the GPOH (Gesellschaft für Pädiatrische Hematologic und Oncologie) and the SIOPEN
      (SIOP (International Society Oncology Pédiatric) Europe Neuroblastoma).

      This protocol will investigate an escalating treatment schedule starting with a
      corticosteroid standard treatment with dexamethasone pulses (first step), which is followed,
      if response has been inadequate after 3 months of treatment, by the addition of CP (second
      step) and, if still no sufficient improvement, by the replacement of CP by Rituximab (third
      step). Treatment intensification is decided on the basis of standardized scoring of OMS/DES
      severity.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The response to treatment schedule as defined by the percentage of patients with disappearance of all symptoms.</measure>
    <time_frame>at 48 weeks after treatment start</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Opsoclonus Myoclonus Syndrome</condition>
  <condition>Neuroblastoma</condition>
  <arm_group>
    <arm_group_label>Dexametasone Cyclophosphamide Rituximab</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone acetate</intervention_name>
    <description>First step:
immunosuppressive treatment with dexamethasone</description>
    <arm_group_label>Dexametasone Cyclophosphamide Rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone and cyclophosphamide</intervention_name>
    <description>second step (in case of insufficient response): immunosuppressive treatment with dexamethasone and cyclophosphamide</description>
    <arm_group_label>Dexametasone Cyclophosphamide Rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone and rituximab</intervention_name>
    <description>third step (in case of insufficient response): immunosuppressive treatment with dexamethasone and rituximab</description>
    <arm_group_label>Dexametasone Cyclophosphamide Rituximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children with newly diagnosed OMS/DES either NB-pos or NB-neg.

        Three out of the following four components are necessary for the diagnosis of OMS/DES:

          -  Opsoclonus or ocular flutter (but not nystagmus)

          -  Ataxia and/or myoclonus

          -  Behavioural change and/or sleep disturbance

          -  Neuroblastoma The diagnosis of OMS/DES may be difficult in some patients. Opsoclonus,
             in particular, may be intermittent or late in onset. A video example will be
             available at www.dancingeyes.org.uk. If uncertain, please contact the national
             coordinator for support in interpreting clinical features.

               -  Age 6 months or over up to less than 8 years (&lt; 8th birthday) The date of
                  diagnosis of OMS/DES is the date on which a doctor confirms the condition to be
                  OMS/DES. The date of symptom onset needs also to be documented.

               -  Treatment start with the standard corticosteroid treatment with dexamethasone
                  pulses as proposed by the guidelines given in this trial protocol (see 11.10,
                  page 71).

               -  In patients with presumed NB-neg OMS/DES, neuroblastoma must be excluded
                  according the guidelines of this trial (see chapter 4.4.1.4, page 30, and
                  appendix 11.9, page 70)

               -  Documented informed consent for treatment and enrolment in the trial by parents
                  / legal representatives.

        Exclusion Criteria:

        •Patients with opsoclonus, myoclonus or ataxia caused by other identified disease (e.g.
        current active CNS infection, neurometabolic disorder or demyelination).

        An identified viral precursor is not an exclusion criterion.

          -  prior or parallel use of chemotherapy (other than required for treatment of the
             neuroblastoma)

          -  Corticoid steroid for OMS/DES or other reasons lasting 14 days or more immediately
             before treatment start according the standard treatment proposed (treatment with
             corticosteroids for less than 14 days will be allowed)

          -  contre-indication of use of one of the experimental study drug (cf Summary of Product
             Characteristics used in this study)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>8 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gudrun Schleiermacher, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Curie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patricia TRESCA, MD</last_name>
    <phone>+33156245765</phone>
    <email>emmanuelle.bouffier@curie.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chu de Bicetre</name>
      <address>
        <city>Kremlin Bicetre</city>
        <state>Kremlin Bicetre Cedex</state>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>TARDIEU Marc, dr</last_name>
    </contact>
    <investigator>
      <last_name>TARDIEU MARC, DR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <state>Lille Cedex</state>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>DESFACHELLES THOMASSIN Anne-Sophie, DR</last_name>
    </contact>
    <investigator>
      <last_name>DESFACHELLES THOMASSIN Anne-Sophie, DR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <state>Lyon Cedex 08</state>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>FAURE CONTER Cécile, DR</last_name>
    </contact>
    <investigator>
      <last_name>FAURE CONTER Cécile, DR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopita D'Enfants de La Timone</name>
      <address>
        <city>Marseille</city>
        <state>Marseille Cedex 5</state>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>COZE CAROLE, DR</last_name>
    </contact>
    <investigator>
      <last_name>COZE Carole, DR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Arnaud de Villeneuve</name>
      <address>
        <city>Montpellier</city>
        <state>Montpellier Cedex 4</state>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>HAOUY Stéphanie, DR</last_name>
    </contact>
    <investigator>
      <last_name>HAOUY Stéphanie, DR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chr de Nantes</name>
      <address>
        <city>Nantes</city>
        <state>NANTES Cedex01</state>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>THEBAUD Estelle, DR</last_name>
    </contact>
    <investigator>
      <last_name>THEBAUD Estelle, DR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu de Nice Archet 2</name>
      <address>
        <city>Nice</city>
        <state>Nice Cedex 03</state>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>LE MEIGNEN DIOP Marion, dr</last_name>
    </contact>
    <investigator>
      <last_name>LE MEIGNEN DIOP Marion, DR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ch Trousseau</name>
      <address>
        <city>Paris</city>
        <state>PARIS Cedex 12</state>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>FASOLA Sylvie, dr</last_name>
    </contact>
    <investigator>
      <last_name>FASOLA Sylvie, dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Hopital Sud</name>
      <address>
        <city>Rennes</city>
        <state>Rennes Cedex 02</state>
        <zip>35056</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>TAQUE Sophie, dr</last_name>
    </contact>
    <investigator>
      <last_name>TAQUE Sophie, dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu de Rouen</name>
      <address>
        <city>Rouen</city>
        <state>Rouen Cedex</state>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>MARIE CARDINE Aude, DR</last_name>
    </contact>
    <investigator>
      <last_name>MARIE CARDINE AUDE, DR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie de La Loire</name>
      <address>
        <city>Saint Priest En Jarez</city>
        <state>Saint Priest En Jarez Cedex</state>
        <zip>42271</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>STEPHAN Jean-Louis, DR</last_name>
    </contact>
    <investigator>
      <last_name>STEPHAN Jean-Louis, dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU DE STRASBOURG HOPITAL Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <state>Strasbourg Cedex</state>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>LUTZ Patrick, dr</last_name>
    </contact>
    <investigator>
      <last_name>LUTZ Patrick, dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Toulouse Hopital Des Enfants</name>
      <address>
        <city>Toulouse</city>
        <state>TOULOUSE Cedex 9</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>RUBIE Hervé, dr</last_name>
    </contact>
    <investigator>
      <last_name>RUBIE Hervé, dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>DEVOLDERE Catherine, DR</last_name>
    </contact>
    <investigator>
      <last_name>DEVOLDERE Catherine, DR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Angers</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>PELLIER Isabelle, DR</last_name>
    </contact>
    <investigator>
      <last_name>PELLIER Isabelle, DR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Jean Minjoz</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>PLOUVIER Emmanuel, DR</last_name>
    </contact>
    <investigator>
      <last_name>PLOUVIER Emmanuel, DR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chr Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>ICHER Céline, DR</last_name>
    </contact>
    <investigator>
      <last_name>ICHER Céline, DR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU CAEN</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>MINCKES ODILE, DR</last_name>
    </contact>
    <investigator>
      <last_name>MINCKES Odile, DR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu D'Estaing</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>KANOLD Justina, DR</last_name>
    </contact>
    <investigator>
      <last_name>KANOLD Justina, DR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>COUILLAULT Gérard, DR</last_name>
    </contact>
    <investigator>
      <last_name>COUILLAULT Gérard, DR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38045</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PLANTAZ Dominique, DR</last_name>
    </contact>
    <investigator>
      <last_name>PLANTAZ Dominique, DR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu de Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>PIGUET Christophe, DR</last_name>
    </contact>
    <investigator>
      <last_name>PIGUET Christophe, DR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Schleiermacher Gudrun, dr</last_name>
    </contact>
    <investigator>
      <last_name>Schleiermacher Gudrun, dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>MILLOT Frédéric, DR</last_name>
    </contact>
    <investigator>
      <last_name>MILLOT Frédéric, dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu de Reims</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>GORDE GROJEAN Stéphanie, DR</last_name>
    </contact>
    <investigator>
      <last_name>GORDE GROJEAN Stéphanie, dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Tours Hopital Clocheville</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>BLOUIN Pascale, dr</last_name>
    </contact>
    <investigator>
      <last_name>BLOUIN Pascale, dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Nancy Brabois</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>CHASTAGNER PASCAL, DR</last_name>
    </contact>
    <investigator>
      <last_name>CHASTAGNER Pascal, DR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>VALTEAU COUANNET Dominique, dr</last_name>
    </contact>
    <investigator>
      <last_name>VALTEAU COUANNET Dominique, DR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>G. Gaslini Institut</name>
      <address>
        <city>Genua</city>
        <zip>16148</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>DE GRANDIS ELISA, DR</last_name>
    </contact>
    <investigator>
      <last_name>DE GRANDIS Elisa, dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Lund</name>
      <address>
        <city>Lund</city>
        <zip>22185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>ORA Ingrid, dr</last_name>
    </contact>
    <investigator>
      <last_name>ORA Ingrid, dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <zip>0X3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>PIKE Michael, dr</last_name>
    </contact>
    <investigator>
      <last_name>PIKE Michael, dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 13, 2014</lastchanged_date>
  <firstreceived_date>May 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Myoclonus</mesh_term>
    <mesh_term>Neuroblastoma</mesh_term>
    <mesh_term>Ocular Motility Disorders</mesh_term>
    <mesh_term>Opsoclonus-Myoclonus Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
